U.S. Markets closed

Does Caladrius Biosciences, Inc. (NASDAQ:CLBS) Have A Particularly Volatile Share Price?

Simply Wall St

Anyone researching Caladrius Biosciences, Inc. (NASDAQ:CLBS) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. First, we have company specific volatility, which is the price gyrations of an individual stock. Holding at least 8 stocks can reduce this kind of risk across a portfolio. The second sort is caused by the natural volatility of markets, overall. For example, certain macroeconomic events will impact (virtually) all stocks on the market.

Some stocks see their prices move in concert with the market. Others tend towards stronger, gentler or unrelated price movements. Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). While we should keep in mind that Warren Buffett has cautioned that 'Volatility is far from synonymous with risk', beta is still a useful factor to consider. To make good use of it you must first know that the beta of the overall market is one. Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Check out our latest analysis for Caladrius Biosciences

What we can learn from CLBS's beta value

Given that it has a beta of 1.60, we can surmise that the Caladrius Biosciences share price has been fairly sensitive to market volatility (over the last 5 years). If this beta value holds true in the future, Caladrius Biosciences shares are likely to rise more than the market when the market is going up, but fall faster when the market is going down. Beta is worth considering, but it's also important to consider whether Caladrius Biosciences is growing earnings and revenue. You can take a look for yourself, below.

NasdaqCM:CLBS Income Statement, January 21st 2020

How does CLBS's size impact its beta?

Caladrius Biosciences is a rather small company. It has a market capitalisation of US$32m, which means it is probably under the radar of most investors. Relatively few investors can influence the price of a smaller company, compared to a large company. This could explain the high beta value, in this case.

What this means for you:

Beta only tells us that the Caladrius Biosciences share price is sensitive to broader market movements. This could indicate that it is a high growth company, or is heavily influenced by sentiment because it is speculative. Alternatively, it could have operating leverage in its business model. Ultimately, beta is an interesting metric, but there's plenty more to learn. In order to fully understand whether CLBS is a good investment for you, we also need to consider important company-specific fundamentals such as Caladrius Biosciences’s financial health and performance track record. I highly recommend you dive deeper by considering the following:

  1. Future Outlook: What are well-informed industry analysts predicting for CLBS’s future growth? Take a look at our free research report of analyst consensus for CLBS’s outlook.
  2. Past Track Record: Has CLBS been consistently performing well irrespective of the ups and downs in the market? Go into more detail in the past performance analysis and take a look at the free visual representations of CLBS's historicals for more clarity.
  3. Other Interesting Stocks: It's worth checking to see how CLBS measures up against other companies on valuation. You could start with this free list of prospective options.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.